Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.31 USD | -3.52% | -3.72% | -45.40% |
14/05 | Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression | MT |
14/05 | Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.40% | 1.54B | |
+64.92% | 62.59B | |
-1.85% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.05% | 26.21B | |
-21.96% | 19.09B | |
+4.21% | 13.08B | |
+25.74% | 12.26B | |
+27.42% | 12.05B |
- Stock Market
- Equities
- NMRA Stock
- News Neumora Therapeutics, Inc.
- Sector Update: Health Care